scispace - formally typeset
Open AccessJournal ArticleDOI

Pro-resolving lipid mediators are leads for resolution physiology

Charles N. Serhan
- 05 Jun 2014 - 
- Vol. 510, Iss: 7503, pp 92-101
Reads0
Chats0
TLDR
The mechanisms of specialized pro-resolving mediators and omega-3 essential fatty acid pathways that could help us to understand their physiological functions are covered.
Abstract
Advances in our understanding of the mechanisms that bring about the resolution of acute inflammation have uncovered a new genus of pro-resolving lipid mediators that include the lipoxin, resolvin, protectin and maresin families, collectively called specialized pro-resolving mediators. Synthetic versions of these mediators have potent bioactions when administered in vivo. In animal experiments, the mediators evoke anti-inflammatory and novel pro-resolving mechanisms, and enhance microbial clearance. Although they have been identified in inflammation resolution, specialized pro-resolving mediators are conserved structures that also function in host defence, pain, organ protection and tissue remodelling. This Review covers the mechanisms of specialized pro-resolving mediators and omega-3 essential fatty acid pathways that could help us to understand their physiological functions.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Maresin 1 resolves aged-associated macrophage inflammation to improve bone regeneration.

TL;DR: The findings here identify resolution of inflammation, and MaR1 itself, to be a point of intervention to improve aged bone healing and to resolve inflammation after tibial fracture injury.
Journal ArticleDOI

Dienals derived from pyridinium salts and their subsequent application in natural product synthesis.

TL;DR: The goal of the present account is to survey the utility of dienals derived from pyridinium salts as the means to establish molecular architecture featured in natural products.
Journal ArticleDOI

Eicosanoid and Specialized Proresolving Mediator Regulation of Lymphoid Cells.

TL;DR: Evidence points toward an essential role of these lipid mediators (LMs) in direct regulation of lymphocyte functions, which are attractive therapeutic targets to control dysregulated innate and adaptive immune responses, promote lymphocyte antitumor activity, and prevent tumor immune evasion.
Journal ArticleDOI

Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application.

TL;DR: The results of this study show for the first time a negative influence of both ACS-H and ACS-L on bone formation demonstrating a substantial need for more sophisticated delivery systems for local stimulation of bone healing in both clinical application and research.
References
More filters
Journal ArticleDOI

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

TL;DR: A better understanding of the molecular basis of myelomonocytic cell plasticity will open new vistas in immunopathology and therapeutic intervention and provide a paradigm for macrophage plasticity and function.
Journal ArticleDOI

Resolution of inflammation: the beginning programs the end.

TL;DR: Emerging evidence now suggests that an active, coordinated program of resolution initiates in the first few hours after an inflammatory response begins, and the mechanism required for inflammation resolution may underpin the development of drugs that can resolve inflammatory processes in directed and controlled ways.
Journal ArticleDOI

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.

TL;DR: It is reported that lipidomic analysis of exudates obtained in the resolution phase from mice treated with ASA and docosahexaenoic acid produce a novel family of bioactive 17R-hydroxy-containing di- and tri-Hydroxy-docosanoids termed resolvins.
Journal ArticleDOI

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

TL;DR: Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function.
Related Papers (5)